圣地亚哥 - 市值1.98亿美元的临床阶段生物科技公司 Cardiff Oncology, Inc. (NASDAQ:CRDF) 宣布其一线RAS突变转移性结直肠癌患者onvansertib联合标准治疗的二期临床试验中期结果积极。根据 InvestingPro 数据，该公司持有的现金多于债务，为其临床项目提供了资金支持。

圣地亚哥 - Cardiff Oncology, Inc. (NASDAQ:CRDF) 周二宣布领导层变动，任命董事会成员Mani Mohindru博士为临时首席执行官，即刻生效。这家目前市值约1.98亿美元的临床阶段生物技术公司，股价在近2.94美元附近交易，过去一周上涨4.63%，尽管过去一年下跌了13.78%。

Cardiff became capital city of Wales in 1955 - but among the many changes of the past 70 years, glimpses of its history remain From bullet holes in a railway bridge to an underground bunker - Cardiff ...

Rubin Colwill has nine Wales caps and was part of squads for Euro 2020 and the 2022 World Cup Rubin Colwill believes Cardiff City's resurgence is helping him to play the best football of his career.

It has been roughly five months since my previous Cardiff Oncology (CRDF) article, where I discussed how the company’s flagship drug, onvansertib, could be one of the biggest stories in small-cap ...